25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

GNPX (Genprex) Stock Analysis
Buy, Hold or Sell?

Let's analyze Genprex together

I guess you are interested in Genprex Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Genprex’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Genprex’s Price Targets

I'm going to help you getting a better view of Genprex Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Genprex Inc

I send you an email if I find something interesting about Genprex Inc.

1. Quick Overview

1.1. Quick analysis of Genprex (30 sec.)










1.2. What can you expect buying and holding a share of Genprex? (30 sec.)

How much money do you get?

How much money do you get?
$8.28
When do you have the money?
1 year
How often do you get paid?
2.6%

What is your share worth?

Current worth
$0.04
Expected worth in 1 year
$-0.05
How sure are you?
28.2%

+ What do you gain per year?

Total Gains per Share
$8.19
Return On Investment
3,350.6%

For what price can you sell your share?

Current Price per Share
$0.24
Expected price per share
$0.14 - $0.3606
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Genprex (5 min.)




Live pricePrice per Share (EOD)
$0.24
Intrinsic Value Per Share
$-3.55 - $-4.01
Total Value Per Share
$-3.50 - $-3.97

2.2. Growth of Genprex (5 min.)




Is Genprex growing?

Current yearPrevious yearGrowGrow %
How rich?$1.3m$8.2m-$6m-284.2%

How much money is Genprex making?

Current yearPrevious yearGrowGrow %
Making money-$4.3m-$6.5m$2.2m51.2%
Net Profit Margin-9,995.5%-6,444.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Genprex (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#698 / 853

Most Revenue
#679 / 853

Most Profit
#385 / 853

Most Efficient
#805 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Genprex?

Welcome investor! Genprex's management wants to use your money to grow the business. In return you get a share of Genprex.

First you should know what it really means to hold a share of Genprex. And how you can make/lose money.

Speculation

The Price per Share of Genprex is $0.2445. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genprex.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genprex, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.04. Based on the TTM, the Book Value Change Per Share is $-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $2.07 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genprex.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.14-57.1%-0.13-52.8%-0.20-79.9%-0.19-75.8%-0.17-69.0%-0.12-49.4%
Usd Book Value Change Per Share-0.07-30.3%-0.02-9.0%-0.06-23.5%-0.08-31.6%-0.03-14.1%0.000.4%
Usd Dividend Per Share0.000.0%2.07846.7%0.000.0%0.69282.2%0.41169.3%0.2186.8%
Usd Total Gains Per Share-0.07-30.3%2.05837.6%-0.06-23.5%0.61250.6%0.38155.2%0.2187.3%
Usd Price Per Share0.23-0.42-1.37-0.99-1.74-1.54-
Price to Earnings Ratio-0.41--0.82--1.84--1.33--2.97--4.11-
Price-to-Total Gains Ratio-3.08--160.88-27.61--47.08--36.45--28.00-
Price to Book Ratio5.48-8.12-7.00-5.72-4.49--92.24-
Price-to-Total Gains Ratio-3.08--160.88-27.61--47.08--36.45--28.00-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.2445
Number of shares4089
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share2.070.41
Usd Book Value Change Per Share-0.02-0.03
Usd Total Gains Per Share2.050.38
Gains per Quarter (4089 shares)8,374.411,551.70
Gains per Year (4089 shares)33,497.656,206.80
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
133859-361334886772-5656197
267717-7226698613543-113012404
3101576-108310048420315-169518611
4135434-144413398227087-226024818
5169293-180516748033859-282531025
6203152-216620097840630-339037232
7237010-252723447647402-395443439
8270869-288826797454174-451949646
9304728-324930147260946-508455853
10338586-361033497067717-564962060

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.038.00.02.6%1.038.00.02.6%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%11.024.04.028.2%11.024.04.028.2%
Dividend per Share1.00.03.025.0%1.00.011.08.3%1.00.019.05.0%1.00.038.02.6%1.00.038.02.6%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%11.024.04.028.2%11.024.04.028.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Genprex Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.074-0.022-70%-0.058-22%-0.077+4%-0.035-53%0.001-7043%
Book Value Per Share--0.0420.064-35%0.245-83%0.303-86%0.642-94%0.411-90%
Current Ratio--0.8441.118-25%2.412-65%3.316-75%19.484-96%17.666-95%
Debt To Asset Ratio--0.6370.543+17%0.303+110%0.336+90%0.214+198%0.184+245%
Debt To Equity Ratio--1.7511.299+35%0.437+301%0.645+171%0.400+338%0.277+531%
Dividend Per Share---2.070-100%-0%0.690-100%0.414-100%0.212-100%
Enterprise Value--6540945.40013355985.720-51%48114332.830-86%38694991.750-83%75144626.350-91%81093781.179-92%
Eps---0.140-0.129-8%-0.195+40%-0.185+33%-0.169+21%-0.121-13%
Ev To Ebitda Ratio---0.349-0.536+53%-2.478+609%-1.671+378%-4.174+1095%-6.506+1763%
Free Cash Flow Per Share---0.115-0.105-9%-0.156+35%-0.147+28%-0.135+17%-0.090-22%
Free Cash Flow To Equity Per Share---0.063-0.008-87%-0.056-12%-0.055-13%-0.022-66%0.006-1097%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---4.013----------
Intrinsic Value_10Y_min---3.545----------
Intrinsic Value_1Y_max---0.563----------
Intrinsic Value_1Y_min---0.553----------
Intrinsic Value_3Y_max---1.569----------
Intrinsic Value_3Y_min---1.500----------
Intrinsic Value_5Y_max---2.427----------
Intrinsic Value_5Y_min---2.263----------
Market Cap8182632.600+7%7630430.40014111276.220-46%45932346.330-83%33173965.500-77%58073264.700-87%51412470.471-85%
Net Profit Margin----99.9550%-64.4470%-54.8010%-32.8800%-16.8620%
Operating Margin----100.0730%-64.7480%-54.9400%-32.9640%-16.9050%
Operating Ratio---100.198-100%64.748-100%54.982-100%32.989-100%16.918-100%
Pb Ratio5.882+7%5.4858.117-32%7.005-22%5.722-4%4.489+22%-92.240+1782%
Pe Ratio-0.438-7%-0.408-0.818+100%-1.839+351%-1.330+226%-2.966+627%-4.111+907%
Price Per Share0.245+7%0.2280.422-46%1.372-83%0.991-77%1.735-87%1.536-85%
Price To Free Cash Flow Ratio-0.529-7%-0.494-1.056+114%-2.125+331%-1.667+238%-3.738+657%-8.360+1594%
Price To Total Gains Ratio-3.304-7%-3.081-160.877+5122%27.610-111%-47.078+1428%-36.453+1083%-28.003+809%
Quick Ratio--0.5530.709-22%1.486-63%2.805-80%17.914-97%15.958-97%
Return On Assets---1.221-1.009-17%-0.620-49%-0.656-46%-0.444-64%-0.683-44%
Return On Equity---3.360-2.413-28%-0.901-73%-1.244-63%-0.799-76%-0.920-73%
Total Gains Per Share---0.0742.048-104%-0.058-22%0.613-112%0.379-120%0.213-135%
Usd Book Value--1391195.0002136044.000-35%8206026.500-83%10138939.250-86%21477251.750-94%13740642.282-90%
Usd Book Value Change Per Share---0.074-0.022-70%-0.058-22%-0.077+4%-0.035-53%0.001-7043%
Usd Book Value Per Share--0.0420.064-35%0.245-83%0.303-86%0.642-94%0.411-90%
Usd Dividend Per Share---2.070-100%-0%0.690-100%0.414-100%0.212-100%
Usd Enterprise Value--6540945.40013355985.720-51%48114332.830-86%38694991.750-83%75144626.350-91%81093781.179-92%
Usd Eps---0.140-0.129-8%-0.195+40%-0.185+33%-0.169+21%-0.121-13%
Usd Free Cash Flow---3864235.000-3516008.000-9%-5206138.500+35%-4930092.500+28%-4512919.369+17%-3024577.138-22%
Usd Free Cash Flow Per Share---0.115-0.105-9%-0.156+35%-0.147+28%-0.135+17%-0.090-22%
Usd Free Cash Flow To Equity Per Share---0.063-0.008-87%-0.056-12%-0.055-13%-0.022-66%0.006-1097%
Usd Market Cap8182632.600+7%7630430.40014111276.220-46%45932346.330-83%33173965.500-77%58073264.700-87%51412470.471-85%
Usd Price Per Share0.245+7%0.2280.422-46%1.372-83%0.991-77%1.735-87%1.536-85%
Usd Profit---4674901.000-4321487.750-8%-6535552.250+40%-6089314.000+30%-5607844.850+20%-3940719.821-16%
Usd Revenue---2479.000-100%5788.500-100%2755.833-100%1653.500-100%847.949-100%
Usd Total Gains Per Share---0.0742.048-104%-0.058-22%0.613-112%0.379-120%0.213-135%
 EOD+5 -3MRQTTM+5 -31YOY+10 -243Y+13 -235Y+10 -2610Y+4 -33

3.3 Fundamental Score

Let's check the fundamental score of Genprex Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.438
Price to Book Ratio (EOD)Between0-15.882
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.553
Current Ratio (MRQ)Greater than10.844
Debt to Asset Ratio (MRQ)Less than10.637
Debt to Equity Ratio (MRQ)Less than11.751
Return on Equity (MRQ)Greater than0.15-3.360
Return on Assets (MRQ)Greater than0.05-1.221
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Genprex Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.246
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Genprex Inc

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Fundamental data was last updated by Penke on 2025-09-04 00:33:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Genprex earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Genprex to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genprex Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-9,995.5%+9,995.5%
TTM-9,995.5%YOY-6,444.7%-3,550.7%
TTM-9,995.5%5Y-3,288.0%-6,707.4%
5Y-3,288.0%10Y-1,686.2%-1,601.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--85.5%+85.5%
TTM-9,995.5%-171.0%-9,824.5%
YOY-6,444.7%-210.0%-6,234.7%
3Y-5,480.1%-289.9%-5,190.2%
5Y-3,288.0%-381.1%-2,906.9%
10Y-1,686.2%-520.3%-1,165.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Genprex is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Genprex to theΒ Biotechnology industry mean.
  • -122.1% Return on Assets means thatΒ Genprex generatedΒ $-1.22 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genprex Inc:

  • The MRQ is -122.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -100.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-122.1%TTM-100.9%-21.2%
TTM-100.9%YOY-62.0%-38.9%
TTM-100.9%5Y-44.4%-56.5%
5Y-44.4%10Y-68.3%+23.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-122.1%-11.9%-110.2%
TTM-100.9%-11.9%-89.0%
YOY-62.0%-11.2%-50.8%
3Y-65.6%-12.0%-53.6%
5Y-44.4%-11.7%-32.7%
10Y-68.3%-13.8%-54.5%
4.3.1.3. Return on Equity

Shows how efficient Genprex is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Genprex to theΒ Biotechnology industry mean.
  • -336.0% Return on Equity means Genprex generated $-3.36Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genprex Inc:

  • The MRQ is -336.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -241.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-336.0%TTM-241.3%-94.8%
TTM-241.3%YOY-90.1%-151.1%
TTM-241.3%5Y-79.9%-161.4%
5Y-79.9%10Y-92.0%+12.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-336.0%-14.2%-321.8%
TTM-241.3%-15.2%-226.1%
YOY-90.1%-15.3%-74.8%
3Y-124.4%-16.9%-107.5%
5Y-79.9%-17.5%-62.4%
10Y-92.0%-19.6%-72.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Genprex Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Genprex is operatingΒ .

  • Measures how much profit Genprex makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Genprex to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genprex Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-10,007.3%+10,007.3%
TTM-10,007.3%YOY-6,474.8%-3,532.5%
TTM-10,007.3%5Y-3,296.4%-6,710.9%
5Y-3,296.4%10Y-1,690.5%-1,605.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--154.1%+154.1%
TTM-10,007.3%-280.2%-9,727.1%
YOY-6,474.8%-268.7%-6,206.1%
3Y-5,494.0%-281.5%-5,212.5%
5Y-3,296.4%-350.8%-2,945.6%
10Y-1,690.5%-530.7%-1,159.8%
4.3.2.2. Operating Ratio

Measures how efficient Genprex is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Genprex Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM100.198-100.198
TTM100.198YOY64.748+35.450
TTM100.1985Y32.989+67.209
5Y32.98910Y16.918+16.072
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.952-1.952
TTM100.1982.974+97.224
YOY64.7483.047+61.701
3Y54.9823.835+51.147
5Y32.9894.924+28.065
10Y16.9186.864+10.054
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Genprex Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Genprex is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.84Β means the company has $0.84 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Genprex Inc:

  • The MRQ is 0.844. The company is just not able to pay all its short-term debts. -1
  • The TTM is 1.118. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ0.844TTM1.118-0.274
TTM1.118YOY2.412-1.294
TTM1.1185Y19.484-18.366
5Y19.48410Y17.666+1.818
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8443.480-2.636
TTM1.1183.790-2.672
YOY2.4124.104-1.692
3Y3.3164.609-1.293
5Y19.4845.764+13.720
10Y17.6666.154+11.512
4.4.3.2. Quick Ratio

Measures if Genprex is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Genprex to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.55Β means the company can pay off $0.55 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genprex Inc:

  • The MRQ is 0.553. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.709. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.553TTM0.709-0.156
TTM0.709YOY1.486-0.778
TTM0.7095Y17.914-17.205
5Y17.91410Y15.958+1.956
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5532.938-2.385
TTM0.7093.291-2.582
YOY1.4863.928-2.442
3Y2.8054.393-1.588
5Y17.9145.837+12.077
10Y15.9586.549+9.409
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Genprex Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of GenprexΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Genprex to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.64Β means that Genprex assets areΒ financed with 63.7% credit (debt) and the remaining percentage (100% - 63.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Genprex Inc:

  • The MRQ is 0.637. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.543. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.637TTM0.543+0.093
TTM0.543YOY0.303+0.241
TTM0.5435Y0.214+0.330
5Y0.21410Y0.184+0.030
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6370.339+0.298
TTM0.5430.359+0.184
YOY0.3030.334-0.031
3Y0.3360.341-0.005
5Y0.2140.349-0.135
10Y0.1840.379-0.195
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Genprex is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Genprex to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 175.1% means that company has $1.75 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genprex Inc:

  • The MRQ is 1.751. The company is just able to pay all its debts with equity.
  • The TTM is 1.299. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.751TTM1.299+0.452
TTM1.299YOY0.437+0.863
TTM1.2995Y0.400+0.899
5Y0.40010Y0.277+0.123
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7510.391+1.360
TTM1.2990.436+0.863
YOY0.4370.436+0.001
3Y0.6450.461+0.184
5Y0.4000.461-0.061
10Y0.2770.514-0.237
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Genprex generates.

  • Above 15 is considered overpriced butΒ always compareΒ Genprex to theΒ Biotechnology industry mean.
  • A PE ratio of -0.41 means the investor is paying $-0.41Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genprex Inc:

  • The EOD is -0.438. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.408. Based on the earnings, the company is expensive. -2
  • The TTM is -0.818. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.438MRQ-0.408-0.030
MRQ-0.408TTM-0.818+0.410
TTM-0.818YOY-1.839+1.021
TTM-0.8185Y-2.966+2.148
5Y-2.96610Y-4.111+1.145
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.438-2.539+2.101
MRQ-0.408-2.361+1.953
TTM-0.818-2.657+1.839
YOY-1.839-3.749+1.910
3Y-1.330-3.883+2.553
5Y-2.966-6.353+3.387
10Y-4.111-7.102+2.991
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Genprex Inc:

  • The EOD is -0.529. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.494. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.056. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.529MRQ-0.494-0.036
MRQ-0.494TTM-1.056+0.562
TTM-1.056YOY-2.125+1.070
TTM-1.0565Y-3.738+2.682
5Y-3.73810Y-8.360+4.622
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.529-3.411+2.882
MRQ-0.494-2.951+2.457
TTM-1.056-3.614+2.558
YOY-2.125-4.421+2.296
3Y-1.667-5.258+3.591
5Y-3.738-8.587+4.849
10Y-8.360-9.639+1.279
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Genprex is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 5.48 means the investor is paying $5.48Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Genprex Inc:

  • The EOD is 5.882. Based on the equity, the company is overpriced. -1
  • The MRQ is 5.485. Based on the equity, the company is overpriced. -1
  • The TTM is 8.117. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD5.882MRQ5.485+0.397
MRQ5.485TTM8.117-2.632
TTM8.117YOY7.005+1.113
TTM8.1175Y4.489+3.628
5Y4.48910Y-92.240+96.730
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.8822.206+3.676
MRQ5.4852.027+3.458
TTM8.1172.194+5.923
YOY7.0052.425+4.580
3Y5.7222.571+3.151
5Y4.4893.805+0.684
10Y-92.2404.462-96.702
4.6.2. Total Gains per Share

2.4. Latest News of Genprex Inc

Does Genprex Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Genprex Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-09-12
23:09
Genprex files to sell 25M shares of common stock by selling shareholdersRead
2025-09-05
23:00
Friday's after hours session: top gainers and losersRead
2025-08-22
16:30
BC-Most Active StocksRead
2025-08-22
16:30
Friday's session: gap up and gap down stocksRead
2025-08-20
23:00
Stay updated with the stocks that are on the move in today's after-hours session.Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Genprex Inc.

4.8.1. Institutions holding Genprex Inc

Institutions are holding 2.232% of the shares of Genprex Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Geode Capital Management, LLC0.2525083695765010.0598
2025-03-31HighTower Advisors, LLC0.239907950065673474.962
2025-03-31HRT FINANCIAL LLC0.1410.00014672029644173.6004
2025-03-31UBS Group AG0.128804268636000538.4385
2025-03-31TWO SIGMA SECURITIES, LLC0.12720.00164217423184122.0853
2025-03-31Virtu Financial LLC0.07670.000325424-55000-68.3875
2025-06-30Eqis Capital Management Inc0.050.000316580165800
2025-06-30TCG Advisory Services, LLC0.04680.000115500200014.8148
2025-06-30Vanguard Group Inc0.046201531500
2025-06-30Citigroup Inc0.038012606126060
2025-03-31Corsair Capital Management LLC0.03020.000610000100000
2025-03-31BlackRock Inc0.02860948500
2025-06-30Tower Research Capital LLC0.018105988-13-0.2166
2025-03-31IFP Advisors, LLC0.01350448400
2025-03-31SBI Securities Co Ltd0.0074024411950397.1487
2025-03-31Morgan Stanley - Brokerage Accounts0.00290958-8415-89.7792
2025-03-31Northwestern Mutual Wealth Management Co0.001505125120
2025-03-31Bank of America Corp0.0015049340.818
2025-03-31Advisor Group Holdings, Inc.0.00040148-254-63.1841
2025-03-31Hanson Mcclain Inc0.0004012500
Total 1.25160.003414834+142121+34.3%

4.9.2. Funds holding Genprex Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr0.89750.00012974772825021886.4908
2025-06-30Fidelity Extended Market Index0.165305480500
2025-06-30Fidelity Series Total Market Index0.0507016817-8298-33.04
2025-06-30Spartan Total Market Index Pool G0.00560186900
2025-06-30Fidelity Total Market Index0.00510170300
2025-06-30EC SICAV EverCapital Invms UCITS I Ins I0.00450.0024150000
2025-06-30NT Ext Equity Mkt Idx Fd - NL0.0030100900
2025-06-30Northern Trust Extended Eq Market Idx0.0028091300
2025-06-30NT Ext Equity Mkt Idx Fd - L0.0028091300
2025-06-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.00240783-2-0.2548
2025-07-31State St US Extended Mkt Indx NL Cl C0.0012039500
2025-07-31Vanguard U.S. Eq Idx Β£ Acc0.001034000
2025-06-30BNYM Mellon SL Market Completion UC10.0010335-1-0.2976
2025-06-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.000802583817.2727
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.000702182180
2025-03-31SSgA U.S. Total Market Index Strategy0.0005016642.4691
2025-07-31State St US Ttl Mkt Indx NL Cl A0.0004012000
2025-06-30Northern Trust Wilshire 50000.0004011800
2025-06-30Fidelity U.S. Equity Index Ins Trust001000
2025-06-30BNYM Mellon NSL Mkt Completion Fund Inst005125
Total 1.14570.0025379754+274462+72.3%

5.3. Insider Transactions

Insiders are holding 0.332% of the shares of Genprex Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-04-21Catherine M VaczyBUY50042.8
2023-04-21John Rodney VarnerBUY47542
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets3,828
Total Liabilities2,436
Total Stockholder Equity1,391
 As reported
Total Liabilities 2,436
Total Stockholder Equity+ 1,391
Total Assets = 3,828

Assets

Total Assets3,828
Total Current Assets2,056
Long-term Assets1,771
Total Current Assets
Cash And Cash Equivalents 1,347
Other Current Assets 709
Total Current Assets  (as reported)2,056
Total Current Assets  (calculated)2,056
+/-0
Long-term Assets
Long-term Assets Other 1,771
Long-term Assets  (as reported)1,771
Long-term Assets  (calculated)1,771
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,436
Long-term Liabilities0
Total Stockholder Equity1,391
Total Current Liabilities
Accounts payable 931
Other Current Liabilities 1,506
Total Current Liabilities  (as reported)2,436
Total Current Liabilities  (calculated)2,436
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock33
Retained Earnings -163,439
Other Stockholders Equity 164,797
Total Stockholder Equity (as reported)1,391
Total Stockholder Equity (calculated)1,391
+/-0
Other
Capital Stock33
Cash and Short Term Investments 1,347
Common Stock Shares Outstanding 27,594
Liabilities and Stockholders Equity 3,828
Net Debt -1,347
Net Invested Capital 1,391
Net Working Capital -380



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
> Total Assets 
410
0
0
0
1,911
1,277
1,008
1,267
1,267
1,386
12,891
11,049
9,269
7,476
6,264
4,068
3,534
24,640
24,749
23,352
31,367
51,036
48,731
46,327
42,862
39,409
34,565
29,946
25,085
23,320
15,911
16,644
10,671
12,565
6,605
3,907
4,124
6,010
3,828
3,8286,0104,1243,9076,60512,56510,67116,64415,91123,32025,08529,94634,56539,40942,86246,32748,73151,03631,36723,35224,74924,6403,5344,0686,2647,4769,26911,04912,8911,3861,2671,2671,0081,2771,911000410
   > Total Current Assets 
250
234
0
0
1,639
954
496
401
401
58
12,540
10,689
8,847
7,046
5,802
3,609
2,977
24,032
24,158
22,711
30,715
50,378
48,062
45,645
39,140
35,703
30,901
26,308
21,473
19,942
12,366
12,857
7,532
9,228
4,395
1,918
2,077
4,164
2,056
2,0564,1642,0771,9184,3959,2287,53212,85712,36619,94221,47326,30830,90135,70339,14045,64548,06250,37830,71522,71124,15824,0322,9773,6095,8027,0468,84710,68912,540584014014969541,63900234250
       Cash And Cash Equivalents 
234
-234
0
0
1,602
930
468
374
374
24
12,002
10,310
8,601
6,946
4,497
2,548
2,002
23,080
22,127
21,058
27,320
47,069
44,243
42,021
38,629
34,555
30,053
25,516
20,954
18,083
9,956
11,711
6,738
8,217
2,459
1,488
1,602
3,468
1,347
1,3473,4681,6021,4882,4598,2176,73811,7119,95618,08320,95425,51630,05334,55538,62942,02144,24347,06927,32021,05822,12723,0802,0022,5484,4976,9468,60110,31012,002243743744689301,60200-234234
       Short-term Investments 
0
468
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000004680
       Net Receivables 
0
0
0
0
8
0
0
0
9
1
0
9
9
9
11
0
1
1
0
0
0
0
0
0
0
32
0
35
35
3,359
0
0
0
0
0
0
0
0
0
0000000003,359353503200000001101199901900080000
       Other Current Assets 
16
0
0
0
28
24
28
27
23
66
1,077
741
237
201
1,295
259
172
70
1,136
966
385
201
756
749
1,023
2,231
1,696
1,515
484
1,859
2,410
1,146
794
1,011
1,936
429
476
695
709
7096954764291,9361,0117941,1462,4101,8594841,5151,6962,2311,0237497562013859661,136701722591,2952012377411,07766232728242800016
   > Long-term Assets 
0
-234
0
0
272
322
512
866
866
1,328
351
360
422
430
462
459
558
608
592
641
652
659
670
682
3,722
3,706
3,664
3,638
3,612
3,378
3,545
3,787
3,139
3,337
2,210
1,990
2,047
1,846
1,771
1,7711,8462,0471,9902,2103,3373,1393,7873,5453,3783,6123,6383,6643,7063,7226826706596526415926085584594624304223603511,32886686651232227200-2340
       Property Plant Equipment 
1
0
0
0
5
7
10
9
8
8
14
16
24
26
24
24
45
51
46
42
39
37
39
44
49
42
35
29
23
19
15
11
8
4
2
0
0
0
0
00002481115192329354249443937394246514524242624161488910750001
       Goodwill 
0
0
0
0
0
0
0
560
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000005600000000
       Intangible Assets 
156
0
0
0
241
261
277
297
297
308
323
326
379
389
421
424
491
536
535
588
602
611
620
627
642
644
666
682
702
722
742
763
773
790
0
0
0
0
0
00000790773763742722702682666644642627620611602588535536491424421389379326323308297297277261241000156
       Long-term Assets Other 
0
-234
0
0
26
54
225
560
1,058
1,012
13
18
398
16
16
12
22
22
11
11
11
11
11
11
3,031
3,020
2,963
2,926
2,887
2,637
2,788
3,012
2,347
2,542
2,208
1,989
2,047
1,846
1,771
1,7711,8462,0471,9892,2082,5422,3473,0122,7882,6372,8872,9262,9633,0203,031111111111111222212161639818131,0121,058560225542600-2340
> Total Liabilities 
16
0
0
0
286
170
210
395
395
1,428
301
565
388
231
939
537
511
697
240
376
451
614
1,047
1,162
1,585
2,385
2,154
2,457
2,810
4,835
3,860
4,338
3,254
3,808
2,259
2,242
2,504
2,142
2,436
2,4362,1422,5042,2422,2593,8083,2544,3383,8604,8352,8102,4572,1542,3851,5851,1621,0476144513762406975115379392313885653011,42839539521017028600016
   > Total Current Liabilities 
16
0
0
0
286
170
210
395
395
1,428
301
565
388
231
939
537
511
697
240
376
451
614
1,047
1,162
1,585
2,385
2,154
2,457
2,810
4,835
3,860
4,338
3,254
3,808
2,259
2,242
2,504
2,142
2,436
2,4362,1422,5042,2422,2593,8083,2544,3383,8604,8352,8102,4572,1542,3851,5851,1621,0476144513762406975115379392313885653011,42839539521017028600016
       Short-term Debt 
0
0
0
0
0
0
0
0
0
279
0
0
0
25
61
62
74
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000074626125000279000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
279
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000279000000000
       Accounts payable 
16
0
0
0
110
139
168
363
629
1,149
301
565
295
206
877
475
436
638
182
321
193
339
370
592
973
1,253
683
684
443
2,212
1,498
1,179
1,398
2,152
1,175
1,304
1,074
1,526
931
9311,5261,0741,3041,1752,1521,3981,1791,4982,2124436846831,2539735923703391933211826384364758772062955653011,14962936316813911000016
       Other Current Liabilities 
0
0
0
0
176
31
42
32
202
202
301
565
93
25
61
62
74
59
58
54
258
275
677
570
612
1,132
1,471
1,773
2,367
2,623
2,362
3,159
1,857
1,656
1,084
938
1,430
616
1,506
1,5066161,4309381,0841,6561,8573,1592,3622,6232,3671,7731,4711,13261257067727525854585974626125935653012022023242311760000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
973
1,253
683
684
443
2,212
0
0
0
0
0
0
0
0
0
0000000002,2124436846831,253973000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
26
0
225
560
760
1,012
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000001,0127605602250260000
> Total Stockholder Equity
394
394
0
0
1,625
1,107
798
872
429
-42
12,590
10,484
8,881
7,245
5,325
3,531
3,024
23,943
24,510
22,976
30,916
50,423
47,684
45,165
41,277
37,025
32,411
27,489
22,275
18,485
12,051
12,305
7,416
8,757
4,346
1,665
1,620
3,868
1,391
1,3913,8681,6201,6654,3468,7577,41612,30512,05118,48522,27527,48932,41137,02541,27745,16547,68450,42330,91622,97624,51023,9433,0243,5315,3257,2458,88110,48412,590-424298727981,1071,62500394394
   Common Stock
0
0
0
0
0
0
0
0
12
12
14
15
15
16
16
16
19
33
39
39
43
47
48
48
48
48
48
48
48
52
52
59
0
2
3
5
0
24
33
33240532059525248484848484848474339393319161616151514121200000000
   Retained Earnings Total Equity00000000-120,011-112,0310-94,992-88,910000-68,898-64,912-58,422-53,194-50,419-46,046-40,479-38,054-35,679-31,984-29,825-26,394-24,208-18,146-17,452-16,7860000000
   Accumulated Other Comprehensive Income 
0
392
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000003920
   Capital Surplus 
0
0
0
0
0
0
0
17,656
17,869
18,093
36,784
36,863
38,691
39,213
40,988
41,570
43,484
69,956
74,890
76,130
89,296
115,287
116,535
0
0
0
121,273
122,433
0
130,463
132,010
0
0
0
0
0
0
0
0
00000000132,010130,4630122,433121,273000116,535115,28789,29676,13074,89069,95643,48441,57040,98839,21338,69136,86336,78418,09317,86917,6560000000
   Treasury Stock000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
15,752
15,995
16,867
17,656
0
18,093
36,784
36,863
0
39,213
40,988
41,570
43,484
69,956
74,890
76,130
89,296
115,287
116,535
117,453
119,247
120,717
121,273
122,433
125,054
130,463
132,010
140,005
0
148,412
150,496
152,128
0
162,608
164,797
164,797162,6080152,128150,496148,4120140,005132,010130,463125,054122,433121,273120,717119,247117,453116,535115,28789,29676,13074,89069,95643,48441,57040,98839,213036,86336,78418,093017,65616,86715,99515,7520000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-7
Gross Profit-7-7
 
Operating Income (+$)
Gross Profit-7
Operating Expense-21,167
Operating Income-21,174-21,174
 
Operating Expense (+$)
Research Development10,535
Selling General Administrative10,632,028
Selling And Marketing Expenses10,621,396
Operating Expense21,16721,263,959
 
Net Interest Income (+$)
Interest Income64
Interest Expense-0
Other Finance Cost-0
Net Interest Income64
 
Pretax Income (+$)
Operating Income-21,174
Net Interest Income64
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-21,111-21,237
EBIT - interestExpense = -21,111
-42,755,453
-21,388,282
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-21,111-21,111
Earnings Before Interest and Taxes (EBITDA)-21,104
 
After tax Income (+$)
Income Before Tax-21,111
Tax Provision-0
Net Income From Continuing Ops-21,111-21,111
Net Income-21,388,282
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses21,174
Total Other Income/Expenses Net63-64
 

Technical Analysis of Genprex
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genprex. The general trend of Genprex is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genprex's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Genprex Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Genprex Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.319 < 0.3472 < 0.3606.

The bearish price targets are: 0.1415 > 0.14.

Know someone who trades $GNPX? Share this with them.πŸ‘‡

Genprex Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Genprex Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Genprex Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Genprex Inc.

Genprex Inc Daily Moving Average Convergence/Divergence (MACD) ChartGenprex Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Genprex Inc. The current adx is .

Genprex Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Genprex Inc.

Genprex Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Genprex Inc.

Genprex Inc Daily Relative Strength Index (RSI) ChartGenprex Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Genprex Inc.

Genprex Inc Daily Stochastic Oscillator ChartGenprex Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Genprex Inc.

Genprex Inc Daily Commodity Channel Index (CCI) ChartGenprex Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Genprex Inc.

Genprex Inc Daily Chande Momentum Oscillator (CMO) ChartGenprex Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Genprex Inc.

Genprex Inc Daily Williams %R ChartGenprex Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Genprex Inc.

Genprex Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Genprex Inc.

Genprex Inc Daily Average True Range (ATR) ChartGenprex Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Genprex Inc.

Genprex Inc Daily On-Balance Volume (OBV) ChartGenprex Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Genprex Inc.

Genprex Inc Daily Money Flow Index (MFI) ChartGenprex Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Genprex Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-30MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-08-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-08-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-15STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Genprex Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Genprex Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.246
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Genprex with someone you think should read this too:
  • Are you bullish or bearish on Genprex? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genprex? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Genprex Inc

I send you an email if I find something interesting about Genprex Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Genprex Inc.

Receive notifications about Genprex Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.